A federal jury ordered Takeda to pay nearly $885 million after finding that it illegally delayed generic competition for Amitiza. Pay-for-delay agreements can benefit drug companies while keeping cheaper generics off the market, raising prices and creating deadweight loss for consumers. #PADP8670
